General Biotechnology

Industrial Application of Biological Self-healing Concrete: Challenges and Economical Feasibility

Self-healing concrete has been scrutinized by several researchers and some industrial concrete producers in relation to the remediation of the occurrence of micro-cracks. Such cracks are a quite well known problem that can lead to corrosion of the steel reinforcement and thus to the possible failure of the entire concrete structure. The need to repair these cracks as soon as possible leads to maintenance costs which can be of the order of €130 (direct costs) per m3 of concrete. Recent scientific studies indicate that a Microbial Induced Carbonate Precipitation (MICP), using microbial spores as active agent, can be an alternative for the actual repair methods. However, the production of bacterial spores is yet imposing considerable costs. According to some concrete producers they would be willing to pay about €15 to €20 per m3 of concrete for a bio-based self-healing product. However, the actual cost of spores production and encapsulation represent a total cost which is orders of magnitude higher. This article analyzes the costs for the biological self-healing in concrete and evaluates the industrial challenges it faces. There is an urgent need to develop the production of a bio-additive at much lower costs to make the biological self-healing industrial applicable. Axenic production and a possible non-axenic process to obtain ureolytic spores were analyzed and the costs calculations are presented in this paper.

Industrial Application of Biological Self-healing Concrete: Challenges and Economical Feasibility Read Post »

General Biotechnology

Debt and Taxes: Marginal Tax Rate Changes, Capital Structure, and Innovative Activity in the Biotechnology Sector

The purpose of this investigation was to examine the association between changes in corporate marginal tax rates (MTRs) and measures of both innovative activity and capital structure among publicly-traded biotechnology firms.  Across a 1980-2010 time frame, a five-year distributed Almon lag model was utilized to assess the effect of annual changes in MTRs upon patenting activity, research and development (R&D) expenditures, cash and short-term investments, debt-to-asset ratios, and debt-to-equity ratios.  Across the 99 biotech firms studied, results suggested that increases in MTRs were significantly associated with marked decreases in patents, R&D expenditures, and cash and other short-term investments.  Additionally, large and statistically significant increases in both debt-to-asset and debt-to-equity ratios were observed with annual increases in MTRs.  While this research can not necessarily discern whether capital structure changes occurred either as an ex-ante response to or an ex-post result of MTR increases, the implication of decreased patenting activity warrants continued evaluations of both internal financial decision making and external tax policy.

Debt and Taxes: Marginal Tax Rate Changes, Capital Structure, and Innovative Activity in the Biotechnology Sector Read Post »

General Biotechnology

Using Biotechnology, CSI, and Zombies to Promote Science Education in one of America’s Most Challenging Regions

This paper examines the creation of a forensic biotechnology program that engages students, promotes science learning beyond the classroom and makes available novel STEM opportunities to an area which previously had little biotechnology educational off…

Using Biotechnology, CSI, and Zombies to Promote Science Education in one of America’s Most Challenging Regions Read Post »

General Biotechnology

Biogenerics 2007: How far have we come?

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Biogenerics 2007: How far have we come?

Go to paper

ABSTRACT: The recent approval of a follow-on version of Pfizer’s Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Biogenerics 2007: How far have we come? Read Post »

General Biotechnology

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Go to paper

ABSTRACT: This paper analyses the recent ruling in Kinik Co. v. Int’l Trade Comm’n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings before the US International Trade Commission under the Tariff Act of 1930 (19 USC §1337(a)) – particularly those concerning the importation of products derived from practising US patented processes abroad.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad Read Post »

Biotechblog
Scroll to Top